Early assessment of outcome in cardiogenic shock: Relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels

Critical Care Medicine

Volumn 37, Issue 6, 2009, Pages 1837-1844

  Jarai, Rudolf ^a   Fellner, Barbara ^a   Haoula, Diana ^a   Jordanova, Nelly ^a   Heinz, Gottfried ^b   Karth, Georg Delle ^b   Huber, Kurt ^a   Geppert, Alexander ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical trial; Coagulation; Heparin; Longitudinal studies; Organ dysfunction; Sepsis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART INFARCTION; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CARDIOGENIC SHOCK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMIC PARAMETERS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; SCORING SYSTEM; AGED; BLOOD; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; PATHOPHYSIOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; FEMALE; HEMODYNAMICS; HUMANS; INTERLEUKIN-6; MALE; MYOCARDIAL REVASCULARIZATION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 66449120331     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819fe896     Document Type: Article

References (43)

1. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341: 625-634
2. Picard MH, Davidoff R, Sleeper LA, et al: Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107:279-284
3. Koreny M, Karth GD, Geppert A, et al: Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002; 112:115-119
4. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107: 2998-3002
5. Geppert A, Steiner A, Zorn G, et al: Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002; 30: 1987-1994
6. Geppert A, Dorninger A, Delle-Karth G, et al: Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006; 34: 2035-2042
7. Januzzi J, Camargo C, Anwaruddin S, et al: The N-terminal Pro-BNP investigation of dyspnoe in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-954
8. Sadanandan S, Cannon CP, Chekuri K, et al: Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:564-568
9. Jarai R, Wojta J, Huber K: Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerations. Thromb Haemost 2005; 94:926-932
10. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322
11. Silver MA, Maisel A, Yancy CW, et al: BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10(5 Suppl 3):1-30
12. Brueckmann M, Huhle G, Lang S, et al: Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 112:527-534
13. Charpentier J, Luyt CE, Fulla Y, et al: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665
14. Roch A, Allardet-Servent J, Michelet P, et al: NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33:1001-1007
15. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702
16. Chua G, Kang-Hoe L: Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004; 8:R248-R250
17. Varpula M, Pulkki K, Karlsson S, et al: Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007; 35:1277-1283
18. Januzzi JL, Morss A, Tung R, et al: Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: A prospective cohort study. Crit Care 2006; 10:R37
19. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
20. Geppert A, Steiner A, Delle-Karth G, et al: Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003; 29: 1384-1389
21. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
22. Fincke R, Hochman JS, Lowe AM, et al: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44:340-348
23. Forfia PR, Watkins SP, Rame JE, et al: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005; 45:1667-1671
24. Tung RH, Garcia C, Morss AM, et al: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32:1643-1647
25. Rudiger A, Fischler M, Harpes P, et al: In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol 2008; 126: 28-31
26. Rudiger A, Gasser S, Fischler M, et al: Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140-2144
27. Meyer B, Huelsmann M, Wexberg P, et al: N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007; 35: 2268-2273
28. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al: Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006: 47:91-97
29. McCullough PA, Duc P, Omland T, et al: B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579
30. Hasdai D, Holmes DR Jr, Califf RM, et al: Cardiogenic shock complicating acute myocardial infarction: Predictors of death. GUSTO Investigators. Global Utilization of streptokinase and tissue-plasminogen activator for occluded coronary arteries. Am Heart J 1999; 138(1 Pt 1):21-31
31. DeFilippi C, van Kimmenade RR, Pinto YM: Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 2008; 101:82-88
32. Gutierrez OM, Tamez H, Bhan I, et al: N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: Prognostic value of baseline and follow-up measurements. Clin Chem 2008; 54:1339-1348
33. Hall C: Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6:257-260
34. Kogler H, Schott P, Toischer K, et al: Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation 2006; 113:2724-2732
35. Zhang Q, Moalem J, Tse J, et al: Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol 2005; 510:209-215
36. Goukassian DA, Qin G, Dolan C, et al: Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007; 115:752-762
37. Vellaichamy E, Kaur K, Pandey KN: Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 2007; 28:893-899
38. Tsuruda T, Boerrigter G, Huntley BK, et al: Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91:1127-1134
39. Kawakami R, Saito Y, Kishimoto I, et al: Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 2004; 110:3306-3312
40. Dejam A, Hunter CJ, Tremonti C, et al: Nitrite infusion in humans and nonhuman primates. Endocrine effects, pharmacokinetics, and tolerance formation. Circulation 2007; 116:1821-1831
41. Erusalimsky JD, Moncada S: Nitric oxide and mitochondrial signaling. From physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27:2524-2531
42. Cosby K, Partovi KS, Crawford JH, et al: Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003; 9:1498-1505
43. van der Zander K, Houben AJ, Kroon AA, et al: Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens 2002; 20: 493-499